BR112012018256A2 - - Google Patents
Info
- Publication number
- BR112012018256A2 BR112012018256A2 BR112012018256A BR112012018256A BR112012018256A2 BR 112012018256 A2 BR112012018256 A2 BR 112012018256A2 BR 112012018256 A BR112012018256 A BR 112012018256A BR 112012018256 A BR112012018256 A BR 112012018256A BR 112012018256 A2 BR112012018256 A2 BR 112012018256A2
- Authority
- BR
- Brazil
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31039810P | 2010-03-04 | 2010-03-04 | |
US41282110P | 2010-11-12 | 2010-11-12 | |
US201161438416P | 2011-02-01 | 2011-02-01 | |
PCT/FI2011/000013 WO2011107653A2 (en) | 2010-03-04 | 2011-03-03 | Method for treating parkinson's disease |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112012018256A2 true BR112012018256A2 (pt) | 2011-09-09 |
BR112012018256A8 BR112012018256A8 (pt) | 2017-12-19 |
Family
ID=44065577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012018256A BR112012018256A8 (pt) | 2010-03-04 | 2011-03-03 | método de tratamento de doença de parkinson |
Country Status (15)
Country | Link |
---|---|
US (4) | US20130137729A1 (pt) |
EP (1) | EP2542220B1 (pt) |
JP (2) | JP5774610B2 (pt) |
KR (1) | KR101868326B1 (pt) |
CN (1) | CN102781424B (pt) |
AU (1) | AU2011222856B2 (pt) |
BR (1) | BR112012018256A8 (pt) |
CA (1) | CA2784819C (pt) |
EA (1) | EA026419B1 (pt) |
ES (1) | ES2614179T3 (pt) |
HK (1) | HK1177896A1 (pt) |
IL (1) | IL221744A (pt) |
MX (1) | MX336187B (pt) |
WO (1) | WO2011107653A2 (pt) |
ZA (1) | ZA201205836B (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1907382B1 (en) | 2005-07-26 | 2015-05-27 | Bial-Portela & CA, S.A. | Nitrocatechol derivatives as comt inhibitors |
EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
EP2481410B1 (en) | 2007-01-31 | 2016-07-13 | BIAL - Portela & Ca., S.A. | Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime |
CN102015696A (zh) | 2008-03-17 | 2011-04-13 | 比艾尔-坡特拉有限公司 | 5-[3-(2,5-二氯-4,6-二甲基-1-氧吡啶-3-基)-[1,2,4]噁二唑-5-基]-3-硝基苯-1,2-二醇的晶型 |
KR20120027197A (ko) | 2009-04-01 | 2012-03-21 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법 |
ES2614179T3 (es) * | 2010-03-04 | 2017-05-30 | Orion Corporation | Uso de levodopa, carbidopa y entacapona para el tratamiento de la enfermedad de Parkinson |
US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
WO2012147099A1 (en) * | 2011-04-25 | 2012-11-01 | Suven Nishtaa Pharma Pvt. Ltd. | Pharmaceutical compositions of levodopa, carbidopa and entacapone |
PT3604299T (pt) | 2011-12-13 | 2023-10-31 | Bial Portela & Ca Sa | Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase |
ES2955693T3 (es) | 2012-12-24 | 2023-12-05 | Neurogastrx Inc | Métodos para el tratamiento de trastornos del tracto GI |
US9642810B2 (en) | 2013-03-15 | 2017-05-09 | Mylan Inc. | Formulation containing carbidopa, levodopa, and entacapone |
EP2799065A1 (en) * | 2013-04-30 | 2014-11-05 | Deva Holding Anonim Sirketi | Levodopa carbidopa entacapone pharmaceutical formulations |
WO2015200369A1 (en) | 2014-06-24 | 2015-12-30 | Neurogastrx, Inc. | Prodrugs of metopimazine |
RU2017120184A (ru) * | 2014-11-28 | 2018-12-28 | БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. | Лекарства для замедления течения болезни паркинсона |
JP2018528205A (ja) * | 2015-08-27 | 2018-09-27 | プレクストン・セラピューティクス・ソシエテ・アノニム | レボドパ誘発性ジスキネジア療法のための脳透過性クロモンオキシム誘導体 |
KR20200136008A (ko) * | 2018-03-23 | 2020-12-04 | 롭서 파마슈티컬스 악티에볼라그 | 신경퇴행성 장애의 치료를 위한 약제학적 조성물의 연속 투여 |
CN112741808B (zh) * | 2019-10-29 | 2024-02-06 | 南京济群医药科技股份有限公司 | 一种提高含盐酸苄丝肼口服固体组合物稳定性的方法 |
US10836757B1 (en) | 2020-04-02 | 2020-11-17 | Neurogastrx, Inc. | Polymorphic forms of metopimazine |
US20230181493A1 (en) * | 2020-04-10 | 2023-06-15 | Senda Biosciences, Inc. | Biomarkers related to parkinson's disease and methods of using the same |
EP4223288B1 (en) | 2022-02-07 | 2024-03-06 | Berlirem GmbH | Novel kit of pharmaceutical preparations for the treatment of parkinson's disease |
GB202212082D0 (en) * | 2022-08-18 | 2022-10-05 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
KR20240080457A (ko) * | 2022-11-30 | 2024-06-07 | 주식회사한국파마 | 신경퇴행성 질환 예방 또는 치료용 필름코팅정제 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3462536A (en) | 1960-07-22 | 1969-08-19 | Merck & Co Inc | Method of inhibiting decarboxylase |
DK175069B1 (da) | 1986-03-11 | 2004-05-24 | Hoffmann La Roche | Pyrocatecholderivater |
US5236952A (en) | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
JPH02138A (ja) | 1987-09-18 | 1990-01-05 | Banyu Pharmaceut Co Ltd | L‐ドーパ誘導体 |
GB2238047B (en) | 1989-11-03 | 1993-02-10 | Orion Yhtymae Oy | Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation |
US5607969A (en) | 1992-12-24 | 1997-03-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | L-DOPA ethyl ester to treat Parkinson's disease |
GB2344819A (en) | 1998-12-18 | 2000-06-21 | Portela & Ca Sa | 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones |
FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
US20040166159A1 (en) * | 2002-05-29 | 2004-08-26 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa |
US20060013875A1 (en) * | 2002-05-29 | 2006-01-19 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
US7101912B2 (en) | 2002-12-06 | 2006-09-05 | Xenoport, Inc. | Carbidopa prodrugs and derivatives, and compositions and uses thereof |
WO2005063696A2 (de) | 2003-12-31 | 2005-07-14 | Cilag Ag | Neue kristalline formen von entacapone und deren herstellung |
MXPA06014132A (es) | 2004-06-04 | 2007-03-07 | Xenoport Inc | Profarmacos de levodopa y sus composiciones y usos. |
WO2006037061A2 (en) * | 2004-09-28 | 2006-04-06 | Farouk Karoum | Compositions and methods of using d-dopa to treat parkinson's disease |
SI1896006T1 (sl) * | 2005-06-08 | 2010-02-26 | Orion Corp | Postopek za izdelavo granul, ki vsebujejo entakapon, za oralne odmerne oblike |
MY148644A (en) | 2005-07-18 | 2013-05-15 | Orion Corp | New pharmaceutical compounds |
EP1907382B1 (en) * | 2005-07-26 | 2015-05-27 | Bial-Portela & CA, S.A. | Nitrocatechol derivatives as comt inhibitors |
EP1959948B1 (en) | 2005-12-05 | 2012-07-18 | XenoPort, Inc. | Levodopa prodrug mesylate, compositions thereof, and uses thereof |
US8741342B2 (en) | 2006-10-30 | 2014-06-03 | Wockhardt Research Centre | Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa |
MX2010009043A (es) | 2008-02-28 | 2010-10-25 | Bial Portela & Ca Sa | Composicion farmaceutica para farmacos poco solubles. |
US9289392B2 (en) * | 2008-08-22 | 2016-03-22 | Wockhardt Ltd. | Extended release pharmaceutical composition of entacapone or salts thereof |
AU2009283814B2 (en) * | 2008-08-22 | 2014-05-01 | Wockhardt Research Centre | Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof |
TR200806646A2 (tr) * | 2008-09-03 | 2009-06-22 | Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. | Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar |
EP2233131A1 (en) | 2009-03-23 | 2010-09-29 | Laboratorios Lesvi, S.L. | Pharmaceutical composition containing levodopa, entacapone and carbidopa |
ES2614179T3 (es) * | 2010-03-04 | 2017-05-30 | Orion Corporation | Uso de levodopa, carbidopa y entacapona para el tratamiento de la enfermedad de Parkinson |
JP5551001B2 (ja) | 2010-06-22 | 2014-07-16 | 株式会社Pfu | 摩擦係数推定装置および摩擦係数推定方法 |
JP2015006373A (ja) * | 2014-07-14 | 2015-01-15 | 株式会社大都技研 | 遊技台 |
-
2011
- 2011-03-03 ES ES11709446.6T patent/ES2614179T3/es active Active
- 2011-03-03 WO PCT/FI2011/000013 patent/WO2011107653A2/en active Application Filing
- 2011-03-03 AU AU2011222856A patent/AU2011222856B2/en active Active
- 2011-03-03 KR KR1020127025501A patent/KR101868326B1/ko active IP Right Grant
- 2011-03-03 CN CN201180012312.9A patent/CN102781424B/zh active Active
- 2011-03-03 CA CA2784819A patent/CA2784819C/en active Active
- 2011-03-03 JP JP2012555453A patent/JP5774610B2/ja active Active
- 2011-03-03 BR BR112012018256A patent/BR112012018256A8/pt not_active IP Right Cessation
- 2011-03-03 EP EP11709446.6A patent/EP2542220B1/en active Active
- 2011-03-03 EA EA201290865A patent/EA026419B1/ru not_active IP Right Cessation
- 2011-03-03 MX MX2012010161A patent/MX336187B/es unknown
- 2011-03-03 US US13/582,427 patent/US20130137729A1/en not_active Abandoned
-
2012
- 2012-08-02 ZA ZA2012/05836A patent/ZA201205836B/en unknown
- 2012-09-02 IL IL221744A patent/IL221744A/en active IP Right Grant
-
2013
- 2013-05-13 HK HK13105664.9A patent/HK1177896A1/zh unknown
-
2014
- 2014-10-02 US US14/504,925 patent/US10857120B2/en active Active
-
2015
- 2015-05-01 JP JP2015094429A patent/JP2015180644A/ja active Pending
-
2020
- 2020-10-07 US US17/064,759 patent/US11771675B2/en active Active
-
2023
- 2023-08-25 US US18/455,759 patent/US20240050394A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2013521263A (ja) | 2013-06-10 |
CA2784819A1 (en) | 2011-09-09 |
IL221744A (en) | 2016-11-30 |
US20210085635A1 (en) | 2021-03-25 |
EP2542220A2 (en) | 2013-01-09 |
KR101868326B1 (ko) | 2018-06-19 |
WO2011107653A3 (en) | 2011-11-03 |
US11771675B2 (en) | 2023-10-03 |
US10857120B2 (en) | 2020-12-08 |
ES2614179T3 (es) | 2017-05-30 |
HK1177896A1 (zh) | 2013-08-30 |
JP5774610B2 (ja) | 2015-09-09 |
WO2011107653A8 (en) | 2012-08-02 |
CA2784819C (en) | 2018-02-13 |
AU2011222856B2 (en) | 2015-10-15 |
US20240050394A1 (en) | 2024-02-15 |
WO2011107653A2 (en) | 2011-09-09 |
EA026419B1 (ru) | 2017-04-28 |
CN102781424A (zh) | 2012-11-14 |
US20150150839A1 (en) | 2015-06-04 |
MX2012010161A (es) | 2012-10-03 |
CN102781424B (zh) | 2016-03-30 |
MX336187B (es) | 2016-01-07 |
AU2011222856A1 (en) | 2012-07-26 |
EP2542220B1 (en) | 2016-11-02 |
BR112012018256A8 (pt) | 2017-12-19 |
JP2015180644A (ja) | 2015-10-15 |
US20130137729A1 (en) | 2013-05-30 |
ZA201205836B (en) | 2014-01-29 |
KR20130006638A (ko) | 2013-01-17 |
EA201290865A1 (ru) | 2013-02-28 |
Similar Documents
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2504 DE 02/01/2019. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |